Novartis AG has swiftly filed suit against the US Food and Drug Administration after the agency’s denial of a second citizen petition opened the door for what the Swiss originator company claims is an “unlawful” approval of a generic version of its Entresto (sacubitril/valsartan), the $3bn heart failure powerhouse.
Key Takeaways
-
Novartis has asked a federal court to set aside the FDA approval of an Entresto generic.
Filed in the US District Court for the District of Columbia, Novartis’ complaint seeks temporary, preliminary, and permanent injunctive relief...
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Pink Sheet for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?